LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.83 6.69

Buy Sell

Overview

Share price change

24h

Current

Min

3.59

Max

3.89

Key metrics
By Trading Economics
Income	-511K -28M
Sales	-13M 2.6M
EPS	-0.47
Profit margin	-1,077.401
Employees	141
EBITDA	-455K -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+311.41% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-23M 212M
Previous open	-2.86
Previous close	3.83

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 maj 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 maj 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 maj 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 maj 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 maj 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 maj 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 maj 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 maj 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 maj 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 maj 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 maj 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 maj 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 maj 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 maj 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 maj 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 maj 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 maj 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 maj 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 maj 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 maj 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

311.41% upside

12 Months Forecast

Average 15.14 USD 311.41%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.